QUOTED. Feb. 19. 2018. Dan Bournstein.
Executive Summary
Check out what Saluda Medical President Dan Bournstein had to say about the firm's responsive, closed-loop spinal cord stimulation technology for which it is seeking CE mark this year and FDA approval by 2020.
“Our goal is to use this information to develop a stimulation response curve similar to a pharmacological dose response curve, so that when SCS is chosen for patients with chronic pain, outcomes are more predictable and sustainable.” – Dan Brounstein, president, Saluda Medical Pty Limited
- Find out more: Start-Up Spotlight: Saluda Hopes To 'Evoke' From Down Under With First Closed-Loop Spine-Stim System
Click here for a free trial of Medtech Insight